81 related articles for article (PubMed ID: 23622906)
1. Rationale and design of the LEADERS FREE trial: A randomized double-blind comparison of the BioFreedom drug-coated stent vs the Gazelle bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy.
Urban P; Abizaid A; Chevalier B; Greene S; Meredith I; Morice MC; Pocock S
Am Heart J; 2013 May; 165(5):704-9. PubMed ID: 23622906
[TBL] [Abstract][Full Text] [Related]
2. Percutaneous Coronary Interventions Using a Ridaforolimus-Eluting Stent in Patients at High Bleeding Risk.
Kornowski R; Konigstein M; Jonas M; Assali A; Vaknin-Assa H; Segev A; Danenberg H; Halabi M; Roguin A; Kerner A; Lev E; Karamasis GV; Johnson TW; Anderson R; Blaxill J; Jadhav S; Hoole S; Witberg G; Issever MO; Ben-Yehuda O; Baumbach A
J Am Heart Assoc; 2024 Jan; 13(2):e029051. PubMed ID: 38214256
[TBL] [Abstract][Full Text] [Related]
3. Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Valgimigli M; Cao D; Makkar RR; Bangalore S; Bhatt DL; Angiolillo DJ; Saito S; Ge J; Neumann FJ; Hermiller J; Picon H; Toelg R; Maksoud A; Chehab BM; Wang LJ; Wang J; Mehran R
Am Heart J; 2021 Jan; 231():147-156. PubMed ID: 33031789
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes with thin versus thick strut polymer-free biolimus-coated stents at 3 years.
Eberli FR; Oldroyd KG; Urban P; Krucoff MW; Morice MC; Tanguay JF; Leon MB; Brunel P; Maillard L; Lipiecki J; Cook S; Berland J; Hovasse T; Carrié D; Schütte D; Sadozai Slama S; Garot P
Open Heart; 2024 Jun; 11(1):. PubMed ID: 38890129
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of drug-eluting stents for patients at high risk of bleedings: A network meta-analysis.
Giacobbe F; Valente E; Morena A; Nebiolo M; Giannino G; De Filippo O; Bruno F; Isaevska E; Richiardi L; Iannaccone M; Zoccai GB; Burzotta F; D'Ascenzo F; Ferrari GM
Catheter Cardiovasc Interv; 2024 May; 103(6):843-855. PubMed ID: 38639169
[TBL] [Abstract][Full Text] [Related]
6. A counseling program on nuisance bleeding improves quality of life in patients on dual antiplatelet therapy: A randomized controlled trial.
Biscaglia S; Tonet E; Pavasini R; Serenelli M; Bugani G; Cimaglia P; Gallo F; Spitaleri G; Del Franco A; Aquila G; Vieceli Dalla Sega F; Tebaldi M; Tumscitz C; Ferrari R; Campo G
PLoS One; 2017; 12(8):e0182124. PubMed ID: 28832589
[TBL] [Abstract][Full Text] [Related]
7. Late Neointimal Regression 5 Years After Polymer-Free Biolimus A9-Coated Stent Implantation: A Case Report.
Kusuda M; Ishihara T; Iida O; Tsujimura T; Hata Y; Toyoshima T; Higashino N; Nakao S; Mano T
CJC Open; 2023 Nov; 5(11):802-804. PubMed ID: 38020337
[No Abstract] [Full Text] [Related]
8. Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk.
Urban P; Meredith IT; Abizaid A; Pocock SJ; Carrié D; Naber C; Lipiecki J; Richardt G; Iñiguez A; Brunel P; Valdes-Chavarri M; Garot P; Talwar S; Berland J; Abdellaoui M; Eberli F; Oldroyd K; Zambahari R; Gregson J; Greene S; Stoll HP; Morice MC;
N Engl J Med; 2015 Nov; 373(21):2038-47. PubMed ID: 26466021
[TBL] [Abstract][Full Text] [Related]
9. Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study.
Naber CK; Urban P; Ong PJ; Valdes-Chavarri M; Abizaid AA; Pocock SJ; Fabbiocchi F; Dubois C; Copt S; Greene S; Morice MC;
Eur Heart J; 2017 Apr; 38(13):961-969. PubMed ID: 27190095
[TBL] [Abstract][Full Text] [Related]
10. Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions: 4- and 12-Month Angiographic Follow-Up and Final 5-Year Clinical Outcomes of the Prospective, Multicenter BioFreedom FIM Clinical Trial.
Costa RA; Abizaid A; Mehran R; Schofer J; Schuler GC; Hauptmann KE; Magalhães MA; Parise H; Grube E;
JACC Cardiovasc Interv; 2016 Jan; 9(1):51-64. PubMed ID: 26762911
[TBL] [Abstract][Full Text] [Related]
11. 2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free Drug-Coated Stents.
Garot P; Morice MC; Tresukosol D; Pocock SJ; Meredith IT; Abizaid A; Carrié D; Naber C; Iñiguez A; Talwar S; Menown IBA; Christiansen EH; Gregson J; Copt S; Hovasse T; Lurz P; Maillard L; Krackhardt F; Ong P; Byrne J; Redwood S; Windhövel U; Greene S; Stoll HP; Urban P;
J Am Coll Cardiol; 2017 Jan; 69(2):162-171. PubMed ID: 27806919
[TBL] [Abstract][Full Text] [Related]
12. Early Clinical Experience with a Polymer-Free Biolimus A9 Drug-Coated Stent in DES-Type Patients Who Are Poor Candidates for Prolonged Dual Anti-Platelet Therapy.
Kinnaird T; Butt M; Abdul F; Yazji K; Hailan A; Gallagher S; Ossei-Gerning N; Chase A; Choudhury A; Smith D; Anderson R
PLoS One; 2016; 11(6):e0157812. PubMed ID: 27362841
[TBL] [Abstract][Full Text] [Related]
13. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis.
Stone GW; Gao R; Kimura T; Kereiakes DJ; Ellis SG; Onuma Y; Cheong WF; Jones-McMeans J; Su X; Zhang Z; Serruys PW
Lancet; 2016 Mar; 387(10025):1277-89. PubMed ID: 26825231
[TBL] [Abstract][Full Text] [Related]
14. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Mauri L; Kereiakes DJ; Yeh RW; Driscoll-Shempp P; Cutlip DE; Steg PG; Normand SL; Braunwald E; Wiviott SD; Cohen DJ; Holmes DR; Krucoff MW; Hermiller J; Dauerman HL; Simon DI; Kandzari DE; Garratt KN; Lee DP; Pow TK; Ver Lee P; Rinaldi MJ; Massaro JM;
N Engl J Med; 2014 Dec; 371(23):2155-66. PubMed ID: 25399658
[TBL] [Abstract][Full Text] [Related]
15. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
[TBL] [Abstract][Full Text] [Related]
16. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
[TBL] [Abstract][Full Text] [Related]
17. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study.
Mehran R; Baber U; Steg PG; Ariti C; Weisz G; Witzenbichler B; Henry TD; Kini AS; Stuckey T; Cohen DJ; Berger PB; Iakovou I; Dangas G; Waksman R; Antoniucci D; Sartori S; Krucoff MW; Hermiller JB; Shawl F; Gibson CM; Chieffo A; Alu M; Moliterno DJ; Colombo A; Pocock S
Lancet; 2013 Nov; 382(9906):1714-22. PubMed ID: 24004642
[TBL] [Abstract][Full Text] [Related]
18. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial.
Pilgrim T; Heg D; Roffi M; Tüller D; Muller O; Vuilliomenet A; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Fahrni T; Moschovitis A; Noble S; Eberli FR; Wenaweser P; Jüni P; Windecker S
Lancet; 2014 Dec; 384(9960):2111-22. PubMed ID: 25189359
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
